JASPER THERAPEUTICS, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
JASPER THERAPEUTICS, INC. (JSPR) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$21.38 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-14
- JASPER THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$14.55M.
- JASPER THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$22.84M, a 172.30% decline year-over-year.
- JASPER THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $31.59M, a 65.35% decline year-over-year.
- JASPER THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was $91.15M.
- JASPER THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$42.95M.
- JASPER THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$15.25M, a 131.35% decline from fiscal 2023.
- JASPER THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $48.64M.
- JASPER THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$46.38M, a 171.50% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$21.38M 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | -$14.55M 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | -$42.95M 10-K · filed 2026-03-30 | |||
| 2025-09-30 | -$20.74M 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | -$32.13M 10-Q · filed 2026-08-14 | |||
| 2025-03-31 | -$22.84M 10-Q · filed 2026-05-14 | |||
| 2024-12-31 | -$15.25M 10-K · filed 2026-03-30 | |||
| 2024-09-30 | $5.62M 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | $19.93M 10-Q · filed 2025-08-13 | |||
| 2024-03-31 | $31.59M 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $48.64M 10-K · filed 2025-02-28 | |||
| 2023-09-30 | $65.62M 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | $77.56M 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | $91.15M 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | -$46.38M 10-K · filed 2024-03-05 | |||
| 2022-09-30 | -$33.68M 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | -$23.82M 10-Q · filed 2023-08-11 | |||
| 2022-03-31 | -$14.23M 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | $64.86M 10-K · filed 2023-03-08 | |||
| 2021-09-30 | $81.07M 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | -$3.08M 10-Q · filed 2022-08-12 | |||
| 2021-03-31 | $3.60M 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | -$6.98M 10-K · filed 2022-03-18 | |||
| 2020-09-30 | -$12.39M 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |